Answers are grounded in this paper and cite their sources.
Trypsin acts as a standard digestive reagent for cell dissociation and passaging in biomedical research. In addition to its role in proteolytic detachment, trypsin activates protease-activated receptor 2 (PAR2), a member of the G protein-coupled receptor, thereby initiating downstream signaling. However, the impact of this unintended PAR2 activation on regulating cellular functions, and its consequent influence on drug candidate evaluation in cell-based assays, has long been overlooked. Here, we demonstrated that trypsin-mediated dissociation, unlike EDTA treatment or mechanical pipetting, potently enhanced cell adhesion, migration, and proliferation across multiple cell types in vitro, and accelerated tumor growth in vivo, primarily via PAR2 signaling. Moreover, trypsin digestion compromised the anti-migratory and anti-tumor efficacy of sorafenib, which could be effectively rescued by PAR2 knockout. Importantly, trypsin-induced PAR2 activation acted as a cumulative proinflammatory stimulus, which peaked at 24 h post-treatment, and facilitated EMT, adhesion, migration, and tumor growth, mechanistically through the NLRP3/caspase-1/IL-1β/IL-18 pathway. Collectively, it revealed a previously unrecognized signaling mechanism by which routine trypsin digestion modulated fundamental cellular behaviors and biased drug efficacy evaluation. The potential confounding effects of PAR2 activation triggered by trypsin dissociation should be carefully considered-and minimized where possible-in experimental design and data analysis within biological and pharmaceutical research.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: